Also trades as: CYBN (AMEX) · $vol 7M
CYBN.NE NEO
Cybin Inc.
1W: -7.0%
1M: +0.7%
3M: +86.4%
YTD: +90.6%
1Y: +73.8%
3Y: +7.1%
5Y: -85.0%
C$16.70 ($11.71)
-0.35 (-2.05%)
Weekly Expected Move ±11.4%
C$13
C$15
C$17
C$19
C$20
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market CapC$404.2M ($283.6M)
52W Range5.3-20.4
Volume100
Avg Volume19,427
Beta-0.95
Dividend—
Analyst Ratings
Company Info
CEOMichael I. Halstead
Employees100
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2020-11-05
Websitehelus.com
100 King Street West, Suite 5600
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc.
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found